Stephens analyst Stephens maintained a Hold rating on Amedisys (NASDAQ:AMED) Inc on Friday, setting a price target of $237, which is approximately 23.86% above the present share price of $191.34.
expects Amedisys Inc to post earnings per share (EPS) of $1.52 for the third quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in Amedisys, with an average price target of $258.67.
The analysts price targets range from a high of $320 to a low of $220.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $537.14 million and a net profit of $68.85 million. The company's market cap is $6.23 billion.
According to TipRanks.com, Stephens analyst Stephens is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 11.3% and a 58.69% success rate.
Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The company was founded by William F. Borne in 1982 and is headquartered in Baton Rouge, LA.